Fulgent Genetics (NASDAQ:FLGT - Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Friday, February 28th. Analysts expect the company to announce earnings of ($0.31) per share and revenue of $75.39 million for the quarter. Parties interested in registering for the company's conference call can do so using this link.
Fulgent Genetics Stock Performance
Shares of NASDAQ:FLGT traded up $0.29 during mid-day trading on Monday, hitting $16.75. The stock had a trading volume of 237,925 shares, compared to its average volume of 231,104. The company's 50 day moving average is $17.61 and its 200-day moving average is $19.71. Fulgent Genetics has a 12-month low of $15.99 and a 12-month high of $25.50. The company has a market cap of $512.33 million, a PE ratio of -3.03 and a beta of 1.39.
Analyst Ratings Changes
FLGT has been the subject of a number of research analyst reports. Piper Sandler reduced their target price on Fulgent Genetics from $26.00 to $22.00 and set a "neutral" rating for the company in a report on Monday, November 11th. StockNews.com downgraded Fulgent Genetics from a "hold" rating to a "sell" rating in a research note on Wednesday, November 27th.
Read Our Latest Stock Report on FLGT
Fulgent Genetics Company Profile
(
Get Free Report)
Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.
See Also
Before you consider Fulgent Genetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fulgent Genetics wasn't on the list.
While Fulgent Genetics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
